Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Cancer research - 1 Mar 2015

Javidi-Sharifi Nathalie, Traer Elie, Martinez Jacqueline, Gupta Anu, Taguchi Takehiro, Dunlap Jennifer, Heinrich Michael C, Corless Christopher L, Rubin Brian P, Druker Brian J, Tyner Jeffrey W

Abstract excerpt

Kinase inhibitors such as imatinib have dramatically improved outcomes for patients with gastrointestinal stromal tumor (GIST), but many patients develop resistance to these treatments. Although in some patients this event corresponds with mutations in the GIST driver oncogenic kinase KIT, other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Synergism
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Immunoprecipitation

Share to Piperazines

Share to Receptor Cross-Talk

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Open in PubMed Open full text

Identifiers

PMID: 25432174
DOI: 10.1158/0008-5472.CAN-14-0573
PMCID: PMC4348216

Genes

FGFR3
KIT
FGF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25432174-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.PMID 25432174Read ↗

Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) ResistanceSemantic proximity Read ↗

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug ResistanceSemantic proximity Read ↗

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours.Semantic proximity Read ↗

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.Semantic proximity Read ↗

FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.Semantic proximity Read ↗

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.Semantic proximity Read ↗

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor.Semantic proximity Read ↗

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.Semantic proximity Read ↗

Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read ↗

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.